Comparison of the Agilent, ROMA/NimbleGen and Illumina platforms for classification of copy number alterations in human breast tumors
Open Access
- 1 January 2008
- journal article
- research article
- Published by Springer Nature in BMC Genomics
- Vol. 9 (1) , 379
- https://doi.org/10.1186/1471-2164-9-379
Abstract
Microarray Comparative Genomic Hybridization (array CGH) provides a means to examine DNA copy number aberrations. Various platforms, brands and underlying technologies are available, facing the user with many choices regarding platform sensitivity and number, localization, and density distribution of probes.Keywords
This publication has 31 references indexed in Scilit:
- A Comparison of DNA Copy Number Profiling PlatformsCancer Research, 2007
- Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancerMolecular Oncology, 2007
- Genome-wide Copy Number Profiling on High-density Bacterial Artificial Chromosomes, Single-nucleotide Polymorphisms, and Oligonucleotide Microarrays: A Platform Comparison based on Statistical Power AnalysisDNA Research, 2007
- Novel patterns of genome rearrangement and their association with survival in breast cancerGenome Research, 2006
- The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurementsNature Biotechnology, 2006
- High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotypingGenome Research, 2006
- Array-CGH and breast cancerBreast Cancer Research, 2006
- Evaluation of gene expression measurements from commercial microarray platformsNucleic Acids Research, 2003
- Detection of Isolated Tumor Cells in Bone Marrow Is an Independent Prognostic Factor in Breast CancerJournal of Clinical Oncology, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001